Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
Monika BratovaJana SkrickovaMagda MatusikovaKarolina HrabcovaLibor HavelLeona KoubkovaMichal HrnciarikJana KrejciOndrej FischerMartin SvatonKristian BratPublished in: Journal of cancer research and clinical oncology (2023)
We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.